Skip to main navigation
Eiger - Header Menu
About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Programs
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (CHI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
Resources
Expanded Access Policy
Contact Us
Privacy Policy
Terms of Use
Eiger - Header Menu
About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Programs
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (CHI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
Resources
Expanded Access Policy
Contact Us
Privacy Policy
Terms of Use
Investors
Event Details
Phase 3 D-LIVR Study Results
December 08, 2022
Click here for webcast
Tools
Print Page
Contact Us
RSS Feeds
Email Alerts
IR Contacts
